Research ArticleClinical Investigation
FDG PET of Recurrent or Metastatic 131I-Negative Papillary Thyroid Carcinoma
Naheel S. Alnafisi, Albert A. Driedger, Geoffrey Coates, Douglas J. Moote and Simon J. Raphael
Journal of Nuclear Medicine June 2000, 41 (6) 1010-1015;
Naheel S. Alnafisi
Albert A. Driedger
Geoffrey Coates
Douglas J. Moote
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
FDG PET of Recurrent or Metastatic 131I-Negative Papillary Thyroid Carcinoma
Naheel S. Alnafisi, Albert A. Driedger, Geoffrey Coates, Douglas J. Moote, Simon J. Raphael
Journal of Nuclear Medicine Jun 2000, 41 (6) 1010-1015;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Role of Diagnostic 131I SPECT/CT in Long-Term Follow-up of Patients with Papillary Thyroid Microcarcinoma
- Clinical Value of Integrated [18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in the Preoperative Assessment of Papillary Thyroid Carcinoma: Comparison With Sonography
- The role of F-18-fluorodeoxyglucose positron emission tomography in the postoperative evaluation of differentiated thyroid cancer
- Comparison of 18F-FDG PET and Bone Scintigraphy in Detection of Bone Metastases of Thyroid Cancer
- 18F-FDG PET/CT in Patients with Suspected Recurrent or Metastatic Well-Differentiated Thyroid Cancer
- Possible Explanations for Patients with Discordant Findings of Serum Thyroglobulin and 131I Whole-Body Scanning
- PET in the follow-up of differentiated thyroid cancer
- Clinical Impact of 18F-FDG PET in Thyroid Carcinoma Patients with Elevated Thyroglobulin Levels and Negative 131I Scanning Results After Therapy
- A Tabulated Summary of the FDG PET Literature